Picture of BioVie logo

BIVI BioVie Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-14.23%
3m+29.33%
6m-33.48%
1yr-65.21%
Volume Change (%)
10d/3m-27.47%
Price vs... (%)
52w High-71.32%
50d MA-12.29%
200d MA-31.87%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-683.56%
Return on Equity-1400.28%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of BioVie EPS forecast chart

Profile Summary

BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

Directors

Last Annual
June 30th, 2021
Last Interim
March 31st, 2022
Incorporated
April 10th, 2013
Public Since
January 14th, 2014
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
28,620,447

BIVI Share Price Performance

Upcoming Events for BIVI

Similar to BIVI

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of 9 Meters Biopharma logo

9 Meters Biopharma

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acer Therapeutics logo

Acer Therapeutics

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email